Selective Glucocorticoid Receptor Modulators (GRMs) retain anti-inflammatory properties while minimizing the metabolic side effects often seen with traditional glucocorticoid therapies, with potential applications in autoimmune diseases and neurodegenerative conditions like AD and multiple sclerosis. The gene discussed is NR3C1; the disease is autoimmune disease.